Exagen (XGN) Insider Chas Mckhann Buys 37,500 Shares

Chas Mckhann made a notable move by purchasing 37,500 shares of XGN on June 9, 2026. This transaction adds to a series of insider buys, reflecting continued interest in the company from those closely tied to it.

Other Institutional Activity in XGN

In recent moves among institutional investors, Wexford Capital LP increased its holdings by 326,077 shares, reaching a total of 792,855 shares valued at approximately $2.38 million. Acadian Asset Management LLC also boosted its position by 274,666 shares, ending with 689,114 shares worth about $2.06 million. Vanguard Capital Management LLC opened a new position with 678,652 shares valued at $2.04 million. Meanwhile, Balysany Asset Management L.P. reduced its stake by 122,555 shares, holding 796,632 shares valued at $2.39 million.

Exagen Inc. Stock Down 47.1%

Shares of XGN traded near $4.45 on Monday. The stock has seen various institutional movements, with some increasing and others decreasing their stakes. This activity comes as the stock navigates its 52-week range and market dynamics.

Insider Buying and Selling at Exagen Inc.

Several insiders have been active in buying XGN shares. On June 9, 2026, Frank Stokes, Scott Kahn, and Chas Mckhann each purchased 37,500 shares. Earlier in March, John Aballi, President and CEO, acquired 100,000 shares at $3.16 and an additional 150,000 shares at no disclosed price. Jeffrey Black, the Chief Financial Officer, also bought 75,000 shares at $3.16 on the same day.

Analysts Set New Price Targets

BTIG maintained a 'buy' rating on XGN, setting a price target of $8 on May 12, 2026. Canaccord Genuity also maintained its 'buy' rating, with a target of $8 on April 20, 2026. Other firms like Craig-Hallum and Keybanc have also kept 'buy' ratings with targets reaching $10.

Bottom Line

Chas Mckhann's recent purchase of XGN shares is part of a broader pattern of insider buying, suggesting confidence in the company's prospects. Institutional investors have shown mixed activity, with some increasing and others trimming their stakes. Analysts remain bullish, maintaining 'buy' ratings with optimistic price targets. As always, it's important to consider these insights as part of a broader investment strategy.